CN100577171C - 治疗重度心力衰竭的药物 - Google Patents

治疗重度心力衰竭的药物 Download PDF

Info

Publication number
CN100577171C
CN100577171C CN200480000735A CN200480000735A CN100577171C CN 100577171 C CN100577171 C CN 100577171C CN 200480000735 A CN200480000735 A CN 200480000735A CN 200480000735 A CN200480000735 A CN 200480000735A CN 100577171 C CN100577171 C CN 100577171C
Authority
CN
China
Prior art keywords
heart failure
benzazepine
compound
present
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN200480000735A
Other languages
English (en)
Chinese (zh)
Other versions
CN1700919A (zh
Inventor
尾崎敦
真木洋介
佐藤修
山村由孝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100577171(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN1700919A publication Critical patent/CN1700919A/zh
Application granted granted Critical
Publication of CN100577171C publication Critical patent/CN100577171C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200480000735A 2003-02-24 2004-02-23 治疗重度心力衰竭的药物 Expired - Lifetime CN100577171C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24
US60/448,878 2003-02-24

Publications (2)

Publication Number Publication Date
CN1700919A CN1700919A (zh) 2005-11-23
CN100577171C true CN100577171C (zh) 2010-01-06

Family

ID=32908667

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200480000735A Expired - Lifetime CN100577171C (zh) 2003-02-24 2004-02-23 治疗重度心力衰竭的药物

Country Status (23)

Country Link
US (2) US7423032B2 (enExample)
EP (2) EP2000142A1 (enExample)
JP (2) JP4771937B2 (enExample)
KR (1) KR100706727B1 (enExample)
CN (1) CN100577171C (enExample)
AR (1) AR043259A1 (enExample)
AT (1) ATE411803T1 (enExample)
AU (2) AU2004212842B9 (enExample)
BR (1) BRPI0405657A (enExample)
CA (1) CA2493475A1 (enExample)
CY (1) CY1108583T1 (enExample)
DE (1) DE602004017283D1 (enExample)
DK (1) DK1596868T3 (enExample)
ES (1) ES2315640T3 (enExample)
MX (1) MXPA05001623A (enExample)
MY (1) MY143740A (enExample)
NO (1) NO335369B1 (enExample)
PL (2) PL218069B1 (enExample)
PT (1) PT1596868E (enExample)
RU (2) RU2346689C2 (enExample)
SI (1) SI1596868T1 (enExample)
TW (1) TWI322689B (enExample)
WO (1) WO2004073716A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
CA2633929A1 (en) 2005-12-27 2007-07-05 Otsuka Pharmaceutical Co., Ltd. Water-soluble benzoazepine compound and its pharmaceutical composition
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
HRP20130920T1 (hr) * 2007-05-15 2013-11-08 Otsuka Pharmaceutical Co., Ltd. Postupak uporabe antagonista vazopresina s kemoterapijom antraciklina radi snižavanja kardiotoksiäśnosti i/ili poboljšanja stope preživljavanja
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
ES2903231T3 (es) 2008-02-26 2022-03-31 Jenavalve Tech Inc Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
WO2011147849A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
JP6563394B2 (ja) 2013-08-30 2019-08-21 イェーナヴァルヴ テクノロジー インコーポレイテッド 人工弁のための径方向に折り畳み自在のフレーム及び当該フレームを製造するための方法
JP6829692B2 (ja) 2015-03-20 2021-02-10 イェーナヴァルヴ テクノロジー インコーポレイテッド 心臓弁プロテーゼ送出システム及び導入体シースにより心臓弁プロテーゼを送出するための方法
EP4403138A3 (en) 2015-05-01 2024-10-09 JenaValve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
CN109475419B (zh) 2016-05-13 2021-11-09 耶拿阀门科技股份有限公司 用于通过引导鞘和装载系统来递送心脏瓣膜假体的心脏瓣膜假体递送系统和方法
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用
JP2025538294A (ja) 2022-11-09 2025-11-27 イエナバルブ テクノロジー インク 拡張可能なインプラントの順次展開のためのカテーテルシステム

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01102124A (ja) 1987-10-14 1989-04-19 Kubota Ltd コンクリート構造体支持構造

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005549A1 (en) 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5753677A (en) * 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
EP0602209A1 (en) 1992-07-02 1994-06-22 Otsuka Pharmaceutical Co., Ltd. Oxytocin antagonist
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JP3002766B2 (ja) 1994-12-09 2000-01-24 大塚製薬株式会社 脳浮腫治療剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
JP4210355B2 (ja) 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
BR0017074A (pt) 2000-01-26 2002-12-03 Warner Lambert Co Combinações de inibidor de ace-antagonista de vasopressina
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
CA2357833C (en) * 2000-10-04 2005-11-15 Warner-Lambert Company Treatment of pulmonary hypertension using vasopressin antagonist
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01102124A (ja) 1987-10-14 1989-04-19 Kubota Ltd コンクリート構造体支持構造

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
effect of long-term treatment with selective vasopressin v1and v2 receptor antagonist on the development of heartfailurein rats. Nishikimi等.journal of cardiovascular pharmacology,Vol.27 No.2. 1996 *
OPC-31260 otsuka,current opinion in cardiovascular. Martinez-castelao.pulmonary &renal investigational drugs,Vol.1 No.3. 1999 *

Also Published As

Publication number Publication date
AU2004212842A1 (en) 2004-09-02
PL373432A1 (en) 2005-08-22
NO20050569L (no) 2005-11-22
RU2346689C2 (ru) 2009-02-20
MY143740A (en) 2011-07-15
CA2493475A1 (en) 2004-09-02
PL218069B1 (pl) 2014-10-31
US20080214523A1 (en) 2008-09-04
DE602004017283D1 (de) 2008-12-04
HK1084037A1 (zh) 2006-07-21
TWI322689B (en) 2010-04-01
EP1596868A4 (en) 2006-03-29
MXPA05001623A (es) 2005-04-25
EP1596868A1 (en) 2005-11-23
AU2004212842B2 (en) 2009-01-08
PT1596868E (pt) 2009-01-14
JP2006518731A (ja) 2006-08-17
US7423032B2 (en) 2008-09-09
CN1700919A (zh) 2005-11-23
WO2004073716A1 (en) 2004-09-02
KR100706727B1 (ko) 2007-04-12
KR20050105972A (ko) 2005-11-08
RU2008133654A (ru) 2010-02-20
SI1596868T1 (sl) 2008-12-31
PL404315A1 (pl) 2013-08-05
ES2315640T3 (es) 2009-04-01
JP4771937B2 (ja) 2011-09-14
NO20050569D0 (no) 2005-02-02
CY1108583T1 (el) 2014-04-09
BRPI0405657A (pt) 2005-07-19
NO335369B1 (no) 2014-12-01
US20050187210A1 (en) 2005-08-25
EP1596868B1 (en) 2008-10-22
AU2009201109A1 (en) 2009-04-09
RU2005102110A (ru) 2005-09-20
TW200418489A (en) 2004-10-01
AU2004212842B9 (en) 2009-03-05
ATE411803T1 (de) 2008-11-15
AR043259A1 (es) 2005-07-20
DK1596868T3 (da) 2008-12-08
EP2000142A1 (en) 2008-12-10
JP2011148806A (ja) 2011-08-04
US7749993B2 (en) 2010-07-06

Similar Documents

Publication Publication Date Title
CN100577171C (zh) 治疗重度心力衰竭的药物
CN111840112B (zh) 鼠尾草酸或其衍生物在制备治疗糖尿病并发症药物中的应用
CN102065856A (zh) 决奈达隆与至少一种利尿药的组合及其治疗用途
HK1084037B (en) Medicament for treating severe heart failure
CN113662930A (zh) 二蒽酮类化合物在制备预防和/或治疗心肌缺血性疾病及其相关病症的药物中的应用
US12336978B2 (en) Pharmaceutical composition containing amlodipine, chlorthalidone, and amiloride and application thereof
EP2386300A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter
US20240115572A1 (en) Methods for treating glioblastomas with sepiapterin
JP3758700B2 (ja) 徐脈性不整脈治療剤
CN113616651B (zh) 一种复方降压药物组合物及其应用
WO2025020917A1 (zh) 用于治疗脏器纤维化相关疾病的药物组合物和方法
CN115957221A (zh) 抗纤维化组合物
JPH08157368A (ja) 脳浮腫治療剤
UA146879U (uk) Фармацевтична композиція

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084037

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1084037

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20100106

CX01 Expiry of patent term